INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2018

In advanced Parkinson's disease, Mucuna pruriens showed similar efficacy to levodopa/carbidopa when tolerated, but half of patients discontinued due to side effects.

Fourteen Parkinson's disease patients with motor fluctuations and dyskinesias received Mucuna pruriens (MP) powder and levodopa/carbidopa (LD/CD) in a randomized crossover design over 16 weeks. Seven patients (50%) discontinued MP prematurely due to gastrointestinal side effects (n=4) or progressive worsening of motor performance (n=3), whereas no patients discontinued during the LD/CD phase. In patients who tolerated MP, the clinical response was similar to LD/CD across all efficacy outcomes. Dropouts later tolerated an MP supernatant water formulation in a study extension (median 16 weeks).

Study type
16-week randomized crossover noninferiority pilot study
Who was studied
14 Parkinson's disease patients with motor fluctuations and dyskinesias
What was measured
Changes in quality of life, motor and non-motor symptoms, good mobility time, tolerability, adverse events, lab indices, and ECG

THE PAPER

Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.

Cilia R, Laguna J, Cassani E, Cereda E, Raspini B, Barichella M, Pezzoli G. Parkinsonism Relat Disord, 2018.

PubMed 29352722 ↗DOI 10.1016/j.parkreldis.2018.01.014 ↗

Brain & mood

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.